<DOC>
	<DOCNO>NCT00328302</DOCNO>
	<brief_summary>The type 1 diabetes patient still normoalbuminuric normotensive , 17 year duration second research kidney biopsy , could enter double blind treatment study Atacand Placebo . The treatment study continue five year treatment end third kidney biopsy . The study hypothesis effect ARB 5 year histopathology pronounce effect histopathology placebo .</brief_summary>
	<brief_title>Diabetes Type 1 , Treatment Study Atacand/Placebo After Kidney Biopsy</brief_title>
	<detailed_description>46 patient perform first kidney biopsy 1992-1994 . After 6 year 29 accept perform second biopsy . During follow-up 10 patient developed complication i.e . hypertension microalbuminuria . 7 patient get treatment follow 3 started treatment second biopsy . 19 patient two kidney biopsy still normoalbuminuric normotensive . 13 enter double-blind treatment study Atacand Placebo . 6 denied participate treatment study . The treatment study continue 5 year end third kidney biopsy . Also rest patient do 2 kidney biopsy ask perform third biopsy .</detailed_description>
	<mesh_term>Candesartan</mesh_term>
	<criteria>Diabetes type 1 patient Normotensive Normoalbuminuric Signed informed consent Female male Over 17 year age Diabetes duration 10 year Hypertension Microalbuminuria Pregnancy Lactation Reduced kidney function Artery stenosis Kidney transplantation Allergy medication study Reduced liver function Alcohol drug abuse Participation another drug clinical test last 30 day Severe diseases i.e . malignancy Previously enrolment present study</criteria>
	<gender>All</gender>
	<minimum_age>17 Years</minimum_age>
	<maximum_age>30 Years</maximum_age>
	<verification_date>June 2000</verification_date>
	<keyword>Diabetes</keyword>
	<keyword>Kidney function</keyword>
	<keyword>24 ambulatory blood pressure</keyword>
	<keyword>Kidney biopsy</keyword>
</DOC>